This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Christopher Patrick Tinworth: Innovator in Androgen Receptor PROTACs
Introduction
Christopher Patrick Tinworth is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of innovative compounds that target androgen receptors.
Latest Patents
Christopher holds 1 patent for his work on Androgen receptor PROTACs. His patent describes certain androgen receptor PROTAC (PROteolysis TArgeting Chimera) compounds that contain a series of 2,4-dioxotetrahydropyrimidinyl derivatives that bind to cereblon. These PROTAC compounds are designed to include an androgen receptor binding moiety, a linker, and a cereblon binding moiety or degron. The medical applications of these compounds are also disclosed in his patent.
Career Highlights
Christopher is associated with GlaxoSmithKline Intellectual Property Development Limited, where he continues to advance his research and development efforts. His work focuses on creating innovative solutions that can have a significant impact on medical treatments.
Collaborations
Christopher collaborates with various professionals in his field, including his coworker Laura Trulli. Their combined expertise contributes to the advancement of their projects and the development of new technologies.
Conclusion
Christopher Patrick Tinworth is a dedicated inventor whose work on androgen receptor PROTACs showcases his commitment to innovation in medicinal chemistry. His contributions are paving the way for future advancements in medical treatments.